Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
3
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
North Korean leader ‘convinced’ dialogue won’t change US hostility
Hanmi Pharma delays phase 3 trials of diabetes treatments until 2017
By 박한나Published : Oct. 28, 2016 - 11:27
[THE INVESTOR] South Korea’s Hanmi Pharmaceutical will embark on Phase 3 clinical trials of its long-acting diabetes treatments in 2017, the company said on Oct. 27.
The late-stage study on so-called GLP-1 diabetes treatments, which was initially set to begin in the fourth quarter this year, was delayed as production of the drug fell behind schedule, according to the drug maker.
In 2015, French pharmaceutical firm Sanofi obtained an exclusive worldwide license to develop and commercialize the treatment. Hanmi retained an exclusive option to co-commercialize the products in Korea and China.
Shares in Hanmi fell 2.2 percent, or 9,000 won (US$7.86) to trade at 400,000 won as of 10:40 a.m.
By Park Han-na (hnpark@heraldcorp.com)
